Physician profile
Amanda G Vantrease
NPI 1619240413
$6,180.30
in general payments reported to CMS, 2019-2025
56 companies · $2,428 in 2025
The $2,428 reported for 2025 was more than what 96% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $77.99 · 2022: $539 · 2023: $1,238 · 2024: $1,898 · 2025: $2,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,269 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,269.18 |
| Education | $293.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $647.21 | 2022-2025 | Rybrevant, Talvey, Tecvayli |
| Novartis Pharmaceuticals Corporation | $510.78 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $400.91 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Pfizer INC. | $347.31 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $319.74 | 2023-2025 | Libtayo |
| Seagen INC. | $319.58 | 2021-2025 | Padcev |
| Astrazeneca Pharmaceuticals LP | $289.44 | 2023-2025 | Tagrisso, Calquence, Lynparza |
| Abbvie INC. | $256.98 | 2022-2025 | |
| Celgene Corporation | $214.61 | 2022-2025 | Reblozyl |
| Exelixis INC. | $177.64 | 2023-2025 | Cabometyx |
| Gilead Sciences, INC. | $164.91 | 2023-2025 | Trodelvy |
| Pharmacosmos Therapeutics INC. | $161.38 | 2024 | Monoferric, Cosela |
| Eisai INC. | $153.94 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $141.81 | 2023-2025 | Fotivda |
| Daiichi Sankyo INC. | $127.23 | 2022-2025 | Enhertu |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $108.06 | 2022-2024 | |
| Beigene USA, INC. | $106.24 | 2023-2025 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $100.93 | 2022-2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $96.17 | 2023-2025 | Ninlaro, Iclusig |
| Karyopharm Therapeutics INC. | $95.27 | 2023-2024 | Xpovio |
| Morphosys, US INC. | $93.84 | 2022-2023 | Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $91.96 | 2022-2025 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $79.15 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $77.33 | 2022-2023 | Imbruvica |
| Genentech USA, INC. | $73.98 | 2024-2025 | Phesgo, Kadcyla, Perjeta |
| Pharmaessentia USA Corporation | $71.36 | 2024-2025 | Besremi |
| Beone Medicines USA, INC. | $69.97 | 2025 | Tevimbra, Brukinsa |
| Stemline Therapeutics INC. | $63.07 | 2023-2025 | Orserdu |
| Incyte Corporation | $56.15 | 2022-2025 | Jakafi, Monjuvi, Niktimvo |
| Emd Serono, INC. | $56.05 | 2023-2025 | Tepmetko |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.17 | 2024-2025 | Gilotrif |
| Genmab U.S., INC. | $50.43 | 2024-2025 | Epkinly |
| Tersera Therapeutics LLC | $49.39 | 2022-2024 | Zoladex |
| Blueprint Medicines Corporation | $42.03 | 2024 | Ayvakit |
| Astellas Pharma US INC | $37.78 | 2022-2023 | Xtandi |
| Array Biopharma INC | $37.49 | 2023-2025 | Mektovi, Lorbrena, Braftovi |
| Ipsen Biopharmaceuticals, INC | $33.95 | 2025 | Onivyde |
| Adaptive Biotechnologies Corporation | $32.74 | 2025 | Clonoseq |
| Avyxa Pharma, LLC | $26.67 | 2025 | |
| Sumitomo Pharma America, INC. | $25.54 | 2024 | Orgovyx |
| Genzyme Corporation | $24.82 | 2023 | |
| Novocure INC. | $24.26 | 2025 | Optune Lua (Novottf-200t) |
| Alnylam Pharmaceuticals INC. | $23.17 | 2024 | Givlaari |
| Geron Corporation | $22.00 | 2025 | Rytelo |
| Verastem, INC. | $21.64 | 2025 | Avmapki Fakzynja Co-Pack |
| Lilly USA, LLC | $21.59 | 2023 | Verzenio, Jaypirca, Retevmo |
| G1 Therapeutics, INC. | $21.32 | 2022 | |
| Glaxosmithkline, LLC. | $20.81 | 2024 | Ojjaara |
| Organon LLC | $20.14 | 2024 | |
| Iovance Biotherapeutics, INC. | $19.21 | 2025 | Amtagvi |
| Taiho Oncology, INC. | $18.73 | 2025 | |
| Puma Biotechnology, INC. | $18.19 | 2025 | |
| Shield Therapeutics INC | $16.95 | 2025 | |
| Adc Therapeutics America, INC. | $16.44 | 2022 | |
| Amgen INC. | $15.86 | 2023 | Lumakras |
| Sobi, INC | $14.98 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Vantrease listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.